AstraZeneca in Cambridge

CAMBRIDGE

UK

Where science thrives

Our new facility – in the centre of the Cambridge Biomedical Campus (CBC) – will be an open, welcoming and vibrant centre that will inspire our team and our partners to push the boundaries of scientific innovation.

Explore Cambridge

AstraZeneca on the CBC

Take a look at the plans for our new global R&D centre and Corporate HQ location.

Working side-by-side

Cambridge key facts

500 million USD

Investment in our new facility

~1,600

AstraZeneca and MedImmune R&D science jobs on the CBC site

>12,000

Healthcare professionals & scientists will work on the CBC

Bringing together world-class capabilities

Our new Cambridge site will bring together small molecule and biologics research and development activity across our main focus areas. It will also be home to a wide range of leading scientific capabilities, including:

Target biology

Our team of world-renowned scientists collaborate to support the identification and validation of targets regulating biological processes which are the fundamental drivers of human disease. Using a variety of tools, including in vivo and in vitro assays and bio-informatic approaches, our scientists rigorously test biological hypotheses across all of our therapy areas in both small molecules and biologics.

Medicinal chemistry

Our medicinal chemistry capabilities enable us to integrate structural, pharmacological, pharmacokinetic and toxicological information to support the innovative design of novel chemical compounds. Pushing the boundaries of medicinal chemistry enables the delivery of new candidate drugs into our pipeline, and is the foundation of small molecule drug discovery across the company.

Protein engineering

Our Antibody Discovery and Protein Engineering Team applies cutting-edge technologies in the discovery of novel therapeutic biologics to change the lives of patients. The team works collaboratively across all therapy areas, using a range of innovative in-house platform technologies such as phage and ribosome display, Fc engineering and novel peptide discovery methodologies. We have an exceptional track record of delivery, having discovered and engineered almost 100 protein therapeutics that have entered the clinic.

Translational science

Our translational expertise enables us to accelerate the development of new druggable targets in human disease and select the right patients in early clinical trials. We do this by embedding human target validation earlier in research, taking an innovative approach to clinical trial design and integrating multiple data sources to share timely scientific insights across our focus areas. As a leader in personalised healthcare, we are also committed to matching new medicines to the patients that will benefit the most. We do this by combining our expertise in companion diagnostics with laboratory science in molecular diagnostics, tissue diagnostics, imaging and protein biomarkers and working with external partners to harness breakthrough technologies, throughout the life-cycle of our medicines.

Biopharmaceutical development

Our Biopharmaceutical Development team develops the process and analytics to produce and characterise product candidates, including the formulations and drug product forms, for delivering medicines to patients. Working closely with research, the team helps define and select the best product candidates to progress into development.

Clinical development

Our Early Clinical Development team designs and delivers early phase development strategies and exploratory studies that build the credentials of novel targets. Clinical Operations delivers global clinical trials for late stage projects across our pipeline, using both internal and external programme and study management expertise. Our leading expertise in large outcomes trials enables us to deliver multi-country, multi-site studies with thousands of patients, many of which include a personalised approach.

Our inspiring scientists

Sharing our passion about what science can do

“I love working for MedImmune because of the passion our people have for great science, and our ability to turn this science into life-improving drugs.”

Strengthening our Cambridge presence

We are building on our proud Medimmune heritage in Cambridge. More than one thousand AstraZeneca and MedImmune employees are already based in the city and working to build strong connections within the local scientific community.

A proud Cambridge heritage: MedImmune in the UK

With over 550 employees, MedImmune’s team at Granta Park is focused on the research and early development of our biologics portfolio. MedImmune has built on the local legacy of Cambridge Antibody Technology (CAT) – acquired by AstraZeneca and integrated with MedImmune in 2007 – where three marketed products (Humira, Benlysta and raxibacumab) were invented. MedImmune Cambridge has strong collaborative links with numerous academics, researchers, foundations and neighbouring companies in the largest biotech cluster in Europe and has an active outreach programme within the local community.

Our current Cambridge facilities

High quality lab and office facilities to accommodate our growing presence in the city.

DaVinci Building

Office facilities located on Melbourn Science Park, accommodating around 400 people from our R&D teams, Global Product and Portfolio Strategy and enabling units.

Central Cambridge

Office facilities located at Academy House and City House in central Cambridge, providing space for colleagues from Global Medicines Development, Global Product and Portfolio Strategy and enabling units.

Working with Horizon Discovery to search for novel, personalised cancer therapies

Our community involvement

With a number of PhD programmes with the University of Cambridge through to our ongoing commitment to STEM programmes in the local community, we are passionate about finding new ways to ensure we support, develop and inspire the next generation of Cambridge scientists.

Social Media

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.